Mind the gap

Abstract

As patent protection for a number of blockbuster drugs expires over the next couple of years, there are serious implications for large pharmaceutical corporations who face increasing competition from the generics drug market. How can Big Pharmas fill the revenue gap caused by a shrinking number of blockbuster drugs on the shelf and in the pipeline?